Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. (Q53252856)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2006

Language	Label	Description	Also known as
English	Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.	scientific article published in June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. (English)

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

United States of America

0 references

Neisseria meningitidis

1 reference

based on heuristic

inferred from title

15

object named as

Rappuoli R

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Elizabeth Miller

11

object named as

Miller E

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Brian D. Plikaytis

12

object named as

Plikaytis B

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

George M Carlone

2

object named as

Carlone GM

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Loek van Alphen

13

object named as

van Alphen L

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

author name string

Borrow R

1

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Rosenstein N

3

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Blake M

4

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Feavers I

5

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Martin D

6

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Zollinger W

7

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Robbins J

8

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Aaberge I

9

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Granoff DM

10

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Poolman J

14

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Danzig L

16

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Hackell J

17

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Danve B

18

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Caulfield M

19

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Lambert S

20

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Stephens D

21

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

24

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

24

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

5093-5107

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Epidemiology of meningococcal meningitis in Angola, 1994-2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Serogroups, serotypes, serosubtypes and antimicrobial susceptibility of Neisseria meningitidis isolates in Casablanca, Morocco

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Recent increase in meningitis Caused by Neisseria meningitidis serogroups A and W135, Yaoundé, Cameroon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Assay parameters and methods of data analysis for the comparison of complement sources in the Neisseria meningitidis serogroup C serum bactericidal assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Frequency of E. coli K antigens in urinary-tract infections in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Epidemiology of Escherichia coli K1 in healthy and diseased newborns

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Safety of vaccines containing meningococcal group B polysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

A human monoclonal macroglobulin with specificity for alpha(2----8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Human immunity to the meningococcus. II. Development of natural immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Naturally-acquired immunity to Neisseria meningitidis group A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Imperfect memory and the development of Haemophilus influenzae type B disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunological Investigations of Meningococcal Disease: III. Brevity of Group C Acquisition Prior to Disease Occurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Impact of meningococcal C conjugate vaccine in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening Method

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Statistical considerations for vaccine immunogenicity trials. Part 1: Introduction and bioassay design and analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome"

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

High-throughput imaging of bacterial colonies grown on filter plates with application to serum bactericidal assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

Rapid serogroup identification of Neisseria meningitidis by using antiserum agar: Prevalence of serotypes in a disease-free military population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

based on heuristic

inferred from DOI database lookup

Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

based on heuristic

inferred from DOI database lookup

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.091

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.03.091

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

release_cr7tcsr3krfnfmjys4wbpun644

1 reference

https://api.fatcat.wiki/v0/release/cr7tcsr3krfnfmjys4wbpun644

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16838413

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53252856&oldid=1838119090"